PTN

Palatin Technologies, Inc.
CAPPED RATING

Palatin Technologies Inc is a biopharmaceutical company engaged in developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with unmet medical need and commercial potential.

Palatin Technologies, Inc. (PTN) is rated C (2.3/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B-); its weakest is Momentum (D). The rating has held at C for 5 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.3 / 5.0
C
Value
B-
Factor Score 3.0 / 5.0
Growth
C
Factor Score 2.4 / 5.0
Profitability
C-
Factor Score 2.0 / 5.0
Momentum
D
Factor Score 1.4 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -4.6
EV / EBITDA -0.4
Rev Growth YoY N/A
Gross Margin 6.2%
Price Return 3M -37.4%
Price Return 12M -27.0%
Catalyst Signal 0.00
Market Cap $11.1M
TTM Revenue $13.2M
Price / Sales 0.8
ROE N/M

Historical Factor Score Progression

Held C for 5 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-14 B- (3.0) C (2.4) C- (2.0) D (1.4) C+ (2.6) C (2.3)
2026-11-07 B- (3.0) C- (2.0) C- (2.0) C (2.4) C+ (2.7) C (2.4)
2026-10-31 B- (3.0) C- (2.0) C (2.2) C- (1.9) C+ (2.7) C (2.4)
2026-10-24 B- (3.0) C- (2.0) C (2.2) C- (1.9) C+ (2.6) C (2.3)
2026-10-17 B- (3.0) C- (1.9) C (2.2) C- (1.9) C+ (2.6) C (2.3)
Page 1 of 6